TAXUS ATLAS trial supports superior deliverability and proven outcomes of TAXUS(R) Liberte(TM) stent system
16 Mai 2006 - 9:39PM
PR Newswire (US)
Boston Scientific's second generation stent compares favorably to
market leading TAXUS Express(2)(TM) stent system, even with more
complex lesions VANCOUVER, May 16 /PRNewswire-FirstCall/ --
Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI; TSX: ANP) today
announced that its corporate partner Boston Scientific Corporation
("BSC") has announced nine-month data from its TAXUS ATLAS clinical
trial. The results confirmed safety and efficacy and demonstrated
the superior deliverability of the TAXUS(R) Liberte(TM)
paclitaxel-eluting stent system compared to the TAXUS
Express(2)(TM) paclitaxel-eluting stent system. BSC made the
announcement at the annual Paris Course on Revascularization
(EuroPCR) held this week in Paris. "The TAXUS ATLAS trial expands
one of the largest DES data collections and extends the consistent
clinical outcomes seen in the TAXUS clinical program to a new stent
platform," said Mark A. Turco, M.D., F.A.C.C., Director, Center for
Cardiac and Vascular Research, Washington Adventist Hospital,
Takoma Park, Maryland, and the trial's co-principle investigator.
"The TAXUS Liberte stent provides improved deliverability and
conformability and the ATLAS trial results support excellent
performance in complex lesions more consistent with evolving
clinical practice patterns." The TAXUS ATLAS trial is a global,
multi-center pivotal study comparing the TAXUS Liberte
paclitaxel-eluting stent system to a case-matched control group of
patients from the TAXUS IV and TAXUS V de novo studies who received
the TAXUS Express(2) paclitaxel-eluting stent system. The trial met
its primary endpoint of nine-month target vessel revascularization
(TVR), a measure of the effectiveness of a coronary stent in
reducing the need for a repeat procedure. The nine-month TVR rate
for the TAXUS Liberte stent was 8.0 percent. The study also
reported a target lesion revascularization (TLR) rate of 5.7
percent for the TAXUS Liberte stent. The TAXUS Liberte arm of the
trial consisted of more complex lesions compared to the control
group. The percent of ACC/AHA B2/C lesions was 75.5 percent
compared to 61.2 percent in the control arm (p less than 0.0001).
Lesion characteristics for the TAXUS Liberte group showed
significant differences (increases) in measures of length, bend,
tortuosity and calcification compared to the control group. Even
with more complex lesions, the TAXUS Liberte stent was associated
with significantly shorter procedural times. The study documented
shorter average procedure times of 47.8 minutes for TAXUS Liberte
versus 53.0 minutes in the control arm (p(equal sign)0.0052). In
addition, the need to use additional stents due to procedural
complications was reduced by nearly 50 percent in the TAXUS Liberte
group (3.1 percent) versus control (6.0 percent). The TAXUS ATLAS
nine-month results also support safety, as demonstrated by low
rates of Major Adverse Cardiac Events (MACE) and stent thrombosis.
All factors of MACE, including cardiac death, myocardial
infarction, TVR and TLR were comparable to control, despite the
higher percentage of complex lesions for the TAXUS Liberte arm. In
addition, stent thrombosis rates were statistically identical
between TAXUS Liberte (0.8 percent or 7/858 patients) and control
stents (0.7 percent or 7/966 patients), indicating comparable
safety of the TAXUS Liberte stent. BSC acquired worldwide exclusive
rights from Angiotech to use paclitaxel to coat its coronary stent
products and has co-exclusive rights to other vascular and
non-vascular products. About Angiotech Pharmaceuticals, Inc.
------------------------------------- Founded in 1992, Angiotech
Pharmaceuticals, Inc. is a global specialty pharmaceutical and
medical device company, with 14 facilities in 6 countries and over
1,500 dedicated employees, that discovers, develops and markets
innovative, minimally invasive treatment solutions for diseases or
complications associated with medical device implants, surgical
interventions and acute injury. To find out more about Angiotech
Pharmaceuticals, Inc. (NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP), please
visit our website at http://www.angiotech.com/. Statements
contained in this press release or in our other written or oral
public communications that are not based on historical or current
fact, including without limitation statements containing the words
"believes," "may," "plans," "will," "estimate," "continue,"
"anticipates," "intends," "expects" and similar expressions,
constitute "forward-looking statements" within the meaning of the
U.S. Private Securities Litigation Reform Act of 1995 and
constitute "forward-looking information" within the meaning of
applicable Canadian securities laws. All such statements are made
pursuant to the "safe harbor" provisions of applicable securities
legislation. Such forward-looking statements are based on
assumptions that involve known and unknown risks, uncertainties and
other factors that may cause the actual results, events or
developments to be materially different from any future results,
events or developments expressed or implied by such forward-looking
statements. Forward-looking statements in this release include the
statements regarding: the applicability of the clinical data to
patient. These statements are subject to risks and uncertainties
that could cause actual results to differ materially from those
projected. These risks and uncertainties include, among others, the
possibility of a change in the regulatory environment in Europe and
the risks and uncertainties described in Angiotech's filings with
the United States Securities and Exchange Commission or the
Canadian securities regulators. The forward looking statements are
also based on a number of assumptions, including the applicability
of the clinical data to patient populations; that the study results
were collected and reported in accordance with the study protocol;
and that the study results have been accurately interpreted. Given
these uncertainties, readers are cautioned not to place undue
reliance on such forward-looking statements. The Company does not
assume the obligation to update any forward-looking statements. FOR
ADDITIONAL INFORMATION: --------------------------- Analysts and
Investors: Janet Craig VP, Investor Relations and Corporate
Communications Angiotech Pharmaceuticals, Inc. (604) 221-6933
Media: Jodi Regts Manager, Corporate Communications Angiotech
Pharmaceuticals, Inc. (604) 221-7930 DATASOURCE: Angiotech
Pharmaceuticals, Inc. CONTACT: Analysts and Investors: Janet Craig,
VP, Investor Relations and Corporate Communications, Angiotech
Pharmaceuticals, Inc., (604) 221-6933; Media: Jodi Regts, Manager,
Corporate Communications, Angiotech Pharmaceuticals, Inc., (604)
221-7930
Copyright
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jul 2023 bis Jul 2024